{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T02:11:01Z","timestamp":1780107061261,"version":"3.54.0"},"reference-count":27,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2019,2,17]],"date-time":"2019-02-17T00:00:00Z","timestamp":1550361600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["analyticalsciencejournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Labelled Comp Radiopharmac"],"published-print":{"date-parts":[[2019,4]]},"abstract":"<jats:p>This study was aimed at evaluating the role of bifunctional chelators DOTA\u2010NCS and CHX\u2010A\u2033\u2010DTPA\u2010NCS used for conjugating <jats:sup>177<\/jats:sup>Lu with Nimotuzumab on the radiochemical yields, purity, <jats:italic>in vitro<\/jats:italic> stability, and specificity of the radioimmunoconjugates to EGFR. Two immunoconjugates were prepared wherein Nimotuzumab was conjugated with the acyclic ligand <jats:italic>p<\/jats:italic>\u2010NCS\u2010Bn\u2010CHX\u2010A\u2033\u2010DTPA and macrocyclic ligand <jats:italic>p<\/jats:italic>\u2010NCS\u2010Bn\u2010DOTA. These were radiolabeled with <jats:sup>177<\/jats:sup>Lu, purified on PD\u201010 column, and characterized by SE\u2010HPLC. <jats:italic>In vitro<\/jats:italic> stability was determined up to 4\u00a0days post preparation. Specificity of the radioimmunoconjugates was ascertained by <jats:italic>in vitro<\/jats:italic> studies in A431 cells while the biodistribution patterns were studied in normal Swiss mice up to 96\u00a0hours post injection. Four to five molecules of CHX\u2010A\u2033\u2010DTPA\/DOTA were attached to one molecule of Nimotuzumab. Radiochemical purity of both <jats:sup>177<\/jats:sup>Lu\u2010CHX\u2010A\u2033\u2010DTPA\u2010Nimotuzumab and <jats:sup>177<\/jats:sup>Lu\u2010DOTA\u2010Nimotuzumab was determined to be greater than 98%. Both the radioimmunoconjugates exhibited good <jats:italic>in vitro<\/jats:italic> stability at 37\u00b0C up to 4\u00a0days post preparation in saline, and their clearance was largely by the hepatobiliary route. The DOTA\u2010 and CHX\u2010A\u2033\u2010DTPA\u2010based radioimmunoconjugates could be prepared with good radiochemical purity, <jats:italic>in vitro<\/jats:italic> stability, and specificity to EGFR. Further studies in EGFR\u2010positive cancers would pave way for them for use in the clinics.<\/jats:p>","DOI":"10.1002\/jlcr.3707","type":"journal-article","created":{"date-parts":[[2019,1,20]],"date-time":"2019-01-20T22:58:23Z","timestamp":1548025103000},"page":"158-165","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Preparation of <sup>177<\/sup>Lu\u2010labeled Nimotuzumab for radioimmunotherapy of EGFR\u2010positive cancers: Comparison of DOTA and CHX\u2010A\u2033\u2010DTPA as bifunctional chelators"],"prefix":"10.1002","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0555-9930","authenticated-orcid":false,"given":"Usha","family":"Pandey","sequence":"first","affiliation":[{"name":"Radiopharmaceuticals Division Bhabha Atomic Research Centre  Mumbai India"},{"name":"Bhabha Atomic Research Centre Homi Bhabha National Institute (HBNI)  Mumbai India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2999-6302","authenticated-orcid":false,"given":"Mythili","family":"Kameswaran","sequence":"additional","affiliation":[{"name":"Radiopharmaceuticals Division Bhabha Atomic Research Centre  Mumbai India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naresh","family":"Gamre","sequence":"additional","affiliation":[{"name":"Radiopharmaceuticals Division Bhabha Atomic Research Centre  Mumbai India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashutosh","family":"Dash","sequence":"additional","affiliation":[{"name":"Radiopharmaceuticals Division Bhabha Atomic Research Centre  Mumbai India"},{"name":"Bhabha Atomic Research Centre Homi Bhabha National Institute (HBNI)  Mumbai India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,2,17]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1677\/erc.1.00600"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2006.04.003"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2009.02.001"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.12037"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.1.1.7509"},{"key":"e_1_2_8_7_1","first-page":"819","article-title":"Profile of nimotuzumab in the treatment of high\u2010grade glioma","volume":"8","author":"Yang Q","year":"2015","journal-title":"Onco Targets Ther"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2013.11.008"},{"key":"e_1_2_8_9_1","first-page":"59","article-title":"Nimotuzumab, a novel monoclonal antibody to the epidermal growth factor receptor, in the treatment of non\u2013small cell lung cancer","volume":"2","author":"Takeda M","year":"2011","journal-title":"Lung Cancer Targets Ther"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1021\/cr3003104"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13139-014-0315-z"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph5010001"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.2174\/1874471011306010004"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2008.04.006"},{"issue":"2","key":"e_1_2_8_15_1","first-page":"166","article-title":"Bifunctional chelates for metal nuclides","volume":"52","author":"Brechbiel MW","year":"2008","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/pros.20856"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nucmedbio.2016.06.004"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.2015.1836"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10967-014-3240-9"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nucmedbio.2013.05.011"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(19)52451-6"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1021\/bc00016a014"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.analchem.5b02572"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nucmedbio.2011.07.001"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1021\/mp4005047"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/slct.201702224"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.2174\/1874471011205040318"},{"issue":"4","key":"e_1_2_8_28_1","first-page":"878","article-title":"Effect of the extent of chelate substitution on the immunoreactivity and biodistribution of 21T\u2010BAT\u2010Lym\u20101 immunoconjugates","volume":"55","author":"Kukis DL","year":"1995","journal-title":"Cancer Res"}],"container-title":["Journal of Labelled Compounds and Radiopharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjlcr.3707","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jlcr.3707","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T19:23:01Z","timestamp":1760642581000},"score":1,"resource":{"primary":{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/10.1002\/jlcr.3707"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,17]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["10.1002\/jlcr.3707"],"URL":"https:\/\/doi.org\/10.1002\/jlcr.3707","archive":["Portico"],"relation":{},"ISSN":["0362-4803","1099-1344"],"issn-type":[{"value":"0362-4803","type":"print"},{"value":"1099-1344","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,17]]},"assertion":[{"value":"2018-10-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-02-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}